Comparing two PET scans to guide treatment for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether two different PET scans can help doctors see how well a new type of targeted therapy (called a TROP2 ADC) is working in people with a specific kind of advanced lung cancer that has stopped responding to standard pills. The goal is to find the best way to monitor treatment and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have a type of lung cancer called non-squamous non-small cell lung cancer that is advanced (stage IIIB/IIIC or IV) and cannot be removed with surgery or treated with radiation.
- Your cancer has a specific gene change called an EGFR mutation (either exon 19 deletion or L858R).
- You have already tried a third-generation EGFR-targeted pill (like osimertinib) and it stopped working.
- You have at least one tumor that can be measured on a scan, and it has not been previously treated with radiation.
- You are generally well enough to carry out daily activities (ECOG score 0 or 1).
- Your organs (blood, liver, kidneys) are functioning well enough, and you have not had a blood transfusion or growth factor injections in the 2 weeks before starting the study.
- You agree to use effective birth control during the study and for 6 months after the last dose.
- You do not have certain other health problems, like severe heart disease, lung disease, or infections that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special PET/CT scan can show how well a Trop2-targeting drug is working in people with advanced lung cancer that has already been treated. It aims to improve how we monitor treatment response.
This trial uses a special PET scan to see if a type of drug called Trop2-ADC is working in people with advanced breast cancer. The scan may help doctors decide if the treatment is right for you.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This trial uses a special PET scan to find a protein called Trop-2 on your cancer cells. It helps doctors decide if a targeted treatment (Trop-2 ADC) might work for you.
This research study analyzes lung cancer tissue samples to understand a protein called TROP2 and how it might help guide treatment decisions. You may qualify if you have non-squamous lung cancer and haven't received prior systemic chemotherapy or immunotherapy for advanced disease.
This trial tests a new drug called datopotamab deruxtecan against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has already been treated. The new drug targets a protein called TROP2 found on cancer cells, which may help slow or stop the cancer's growth.
Hear when a new EGFR Activating Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.